TScan Therapeutics Announces Upcoming Virtual Investor Event
07 nov. 2022 07h00 HE
|
TScan Therapeutics, Inc.
Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors Monday, November 14th at 5:00 PM ET WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc....
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
03 nov. 2022 09h34 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
05 oct. 2022 08h33 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T...
TScan Therapeutics to Participate in Upcoming Investor Conferences
22 sept. 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
12 sept. 2022 07h00 HE
|
TScan Therapeutics, Inc.
Financing supports management’s focus on clinical execution and advancing its ImmunoBank Initial $30 million tranche extends cash runway into the second quarter of 2024 WALTHAM, Mass., Sept. 12,...
TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
07 sept. 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered...
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
10 août 2022 07h00 HE
|
TScan Therapeutics, Inc.
Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs ...
TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
03 août 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T...
TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening Technology
11 juil. 2022 07h00 HE
|
TScan Therapeutics, Inc.
TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to neoadjuvant immunotherapy TCR for...
TScan Therapeutics Appoints Debora Barton, M.D., as Chief Medical Officer
07 juil. 2022 07h00 HE
|
TScan Therapeutics, Inc.
WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T...